Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding

Inclusion Criteria: * Participants are female and have a uterus * Participants are between the ages of 18 and 51 years at the time of consent * Participants have heavy menstrual bleeding as evidenced by their symptoms of subjective increased bleeding volume and desire to seek treatment * The symptom of heavy menstrual bleeding has been present for most of the last 6 months * Participants have regular menstrual cycles between 24 -38 days in length Exclusion Criteria: * Participants who are pregnant or have a positive urine β-hCG * Participants whose bleeding is coming from a cervical, vaginal, urinary or gastrointestinal source * Participants who are found to have or who have a previous diagnosis of uterine or cervical polyps, adenomyosis, or leiomyomas (fibroids) * Participants who are found to have or who have had endometrial hyperplasia, cervical dysplasia or malignancy of any of the vulva, cervix, endometrium, breast or ovaries. * Participants who have ovulatory dysfunction as defined by menstrual cycles that are irregular in frequency and regularity and are often punctuated with periods of amenorrhea * Participants who are found to have or who have been diagnosed with a coagulopathy * Participants who have a current genitourinary infection * Participants who are desirous of becoming pregnant within the next four months * Participants who have untreated or inadequately treated thyroid disease * Participants who have a contraindication to either treatment including hypersensitivity * Participants who are breastfeeding * Participants with mild, moderate or severe hepatic impairment * Participants with moderate or severe renal impairment * Participants with severe asthma not controlled with oral glucocorticoids * Participants with active disease, or history of deep vein thrombosis (DVT), pulmonary embolism (PE), cerebral thrombosis or with family history of thromboembolic disease * Patients with subarachnoid hemorrhage * Patients with acquired disturbances of colour vision * Participants who are already on hormone based treatment including, progesterone only pills, combined oral contraceptive pill (COCP), Intrauterine System (IUS)